NCT00959114View on ClinicalTrials.gov

Safety and Efficacy of ALV003 for the Treatment of Celiac Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

October 31, 2010

Conditions
Celiac Disease
Interventions
BIOLOGICAL

ALV003

ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).

BIOLOGICAL

ALV003 placebo

ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).

Trial Locations (1)

Unknown

FINN-MEDI Research - Clinical Trials Center, Tampere

Sponsors
All Listed Sponsors
lead

Alvine Pharmaceuticals Inc.

INDUSTRY

NCT00959114 - Safety and Efficacy of ALV003 for the Treatment of Celiac Disease | Biotech Hunter | Biotech Hunter